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Abstract
There is an increasing demand for accurate endotyping of patients according to their patho-
genesis to allow more targeted treatment. We explore a combination of blood-based joint tis-
sue metabolites (neoepitopes) to enable patient clustering through distinct disease profiles.
We analysed data from two RA studies (LITHE (N = 574, follow-up 24 and 52 weeks),
OSKIRA-1 (N = 131, follow-up 24 weeks)). Two osteoarthritis (OA) studies (SMC01 (N =
447), SMC02 (N = 81)) were included as non-RA comparators. Specific tissue-derived
neoepitopes measured at baseline, included: C2M (cartilage degradation); CTX-I and PINP
(bone turnover); C1M and C3M (interstitial matrix degradation); CRPM (CRP metabolite)
and VICM (macrophage activity). Clustering was performed to identify putative endotypes.
We identified five clusters (A-E). Clusters A and B were characterized by generally higher
levels of biomarkers than other clusters, except VICM which was significantly higher in clus-
ter B than in cluster A (p<0.001). Biomarker levels in Cluster C were all close to the median,
whilst Cluster D was characterised by low levels of all biomarkers. Cluster E also had low
levels of most biomarkers, but with significantly higher levels of CTX-I compared to cluster
D. There was a significant difference in ΔSHP score observed at 52 weeks (p<0.05). We
describe putative RA endotypes based on biomarkers reflecting joint tissue metabolism.
These endotypes differ in their underlining pathogenesis, and may in the future have utility
for patient treatment selection.
Introduction
Rheumatoid Arthritis (RA) is a heterogeneous chronic inflammatory and autoimmune dis-
ease, characterised by pain and swelling of joints, progressive joint deterioration, bone







Citation: Blair JPM, Bager C, Platt A, Karsdal M,
Bay-Jensen A-C (2019) Identification of
pathological RA endotypes using blood-based
biomarkers reflecting tissue metabolism. A
retrospective and explorative analysis of two phase
III RA studies. PLoS ONE 14(7): e0219980. https://
doi.org/10.1371/journal.pone.0219980
Editor: Oreste Gualillo, SERGAS and IDIS, SPAIN
Received: January 14, 2019
Accepted: July 5, 2019
Published: July 24, 2019
Copyright: © 2019 Blair et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data is available on
request. Data cannot be made publicly available
due to data privacy concerns of this sensitive
patient data which is of a clinical nature.
Requests to access the data should be sent to
legal@nordicbio.com attn. head of Immuno-
science. Biomarker data, which are not linked to
patient data (including clinical assessments
recordings), may be readily available, whereas
clinical data will need approval from ethical board
appointed by AstraZeneca. Authors did not have
direct access to patient identifying information.
erosions and impaired function, often leading to disability[1]. Due to the heterogeneity and
the complex aetiology of the disease, rates of drug response in RA patients varies from com-
pound to compound. A systematic review of effectiveness of anti-TNF compounds found the
mean percentage of ACR-20 responders was 60.8% and EULAR responders 70.5%, leaving a
large proportion still unresponsive[2]. Development and selection of treatment is therefore a
challenging process making it difficult to deliver targeted treatments.
Currently treatment is based on the use of disease activity markers such as disease activity
scores (e.g. DAS28), radiographic scores and other clinical assessments to gauge a patient’s
state, progress and response to treatment. This does not take into account more intricate path-
ological differences between the patients but rather more systemic levels of inflammation. By
adopting a precision medicine approach, one aims to improve response rates through the use
of biomarkers facilitating the identification of patients most likely to benefit[3].
RA may comprise of multiple clinical and molecular endotypes[4], being defined as sub-
types of a disease with distinctive underlying pathological mechanisms[4,5]. A patient’s clinical
presentation, response to treatment and rates of disease progression may be determined by a
patient’s endotype. Thus, well characterised endotypes may provide patients and physicians
with a means for targeted treatment against a patient’s individual molecular disease pathogen-
esis. Moreover, endotypes may provide insight into novel pathways and thereby discovery of
new drug mode[4].
In order to begin designing such a tool to identify distinct endotypes in RA, it is vital to
have an understanding of underlying pathological mechanisms. Type I, II and III collagens are
the most prevalent structural proteins in the joint, and among the most prevalent in the body
[6]. Various clinical and preclinical studies have shown in increase in type I, II and III collagen
degradation in RA due to an increase in proteolytic activity[7,8]. Multiple biomarkers have
been developed that measure such tissue metabolites in blood of patients with arthritis[9].
Examples of such tissue metabolites are: i) CTX-I and PINP, which are measures of bone
resorption and formation;[8,10] ii) C1M and C3M, which reflect MMP mediated degradation
of collagen 1 and 3 respectively;[11,12] iii) C2M, measuring MMP mediated collagen 2 degra-
dation;[13] iv) CRPM, CRP degradation;[14] and v) VICM, MMP driven citrullinated vimen-
tin degradation[15]. These are also examples of tissue metabolites which have been shown to
elevated in RA, associated with disease activity[16] and treatment response[9]. As these metab-
olites are a reflection of tissue associated disease mechanism, they could be useful tools to iden-
tify different endotypes in RA.
The aim of this study was to demonstrate how different putative endotypes representing




Four cohorts were pooled for this study, including two RA studies; LITHE (N = 1196,
NCT00106535) and OSKIRA-1 (N = 918, NCT01197521) and two OA studies; SMC01
(N = 1176, NCT00486434) and SMC02 (N = 1030, NCT00704847) all of which have been
described in detail before[17–20]. The RA studies included patients with moderate to severe
disease and with a high disease activity. Patients from the OA studies were included in order
to enrich the cohort with a disease population with low inflammation but with known joint
disease as characterised by X-ray and by symptomatic scores, providing a broader range of
biomarker levels. Patients were randomly selected from the clinical trials to participate in
biomarker sub-studies of all phase III clinical trials for RA (LITHE and OSKIRA-1) and
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placebo arms of OA studies (SMC01 and SMC02) (Fig 1). Patients in LITHE all had active
moderate to severe RA with inadequate response to methotrexate (MTX). OSKIRA-1 had
similar inclusion criteria, selecting patients with active RA and inadequate response to
MTX. Both SMC trials recruited patients with a medical history and symptoms of knee OA.
Further details of the patient demographics from each study can be read in Table 1. Patients
from any cohort with missing biomarker measurements at baseline were excluded from
the study. No ethical approval was required as no patient recruitment or data collection was
carried out for this study. The authors did not have access to any identifying participant
information.
Endpoints in each RA study were measured according to ACR and EULAR criteria[21],
and include radiographic measurements, DAS-28 disease activity scores as well as patient
and physician reported outcomes. Erosion (ERN), joint space narrowing (JSN) and modified
sharp score (SHP) were calculated at baseline and 24 weeks for LITHE and OSKIRA, and at 52
weeks for LITHE. Delta (Δ) ERN, JSN and SHP were calculated by subtracting baseline score
from follow-up scores at week 24 and 52 where available for the placebo patients, to remove
treatment bias.
Fig 1. Four biomarker sub-studies of clinical trials were pooled for clustering before further analysis of each
cluster. A random selection of patients from the RA clinical trials were selected for biomarker analysis. Patients with
missing data from the panel of biomarkers analysed were removed from the study when included in the arthritic
cohort.
https://doi.org/10.1371/journal.pone.0219980.g001
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Biomarker measurements
Several serological biomarkers were measured in each cohort and selected due to the specific
tissue metabolite they represented. A total of 20 biomarkers were measured across all trials,
with 7 biomarkers common to all studies and analysed post hoc in this paper. All samples were
destroyed after measurement according protocol. These included: C2M (cartilage degrada-
tion)[22,23]; CTX-I[24] and PINP (bone resorption and formation)[13,25]; C1M and C3M
(interstitial matrix degradation)[9,11,12,26]; CRPM (CRP metabolite)[14,23], and VICM
(macrophage activity)[16,27]. The biomarkers were measured in serum samples following the
manufactures protocols and under Good Laboratory Practice (GLP).
All variables were calibrated according to the assay they had been measured in to control
for possible batch effect. Each biomarker was then log transformed and min-max normalised
to allow for direct comparison of each of the variables.
Clustering protocol
Three statistical heuristics were evaluated in order to identify cluster tendency and the number
of inherent clusters in the data. The GAP statistic[28], silhouette method[29] and elbow
method[30] were all used to assess this, with the majority rule used to indicate number of
clusters.
Patient clustering was then performed using Ward hierarchical clustering. The statistical
significance of the resulting cluster separations was assessed using permutation testing as
described by Serviss et al.[31] using 100 iterations. ANOVA and Chi squared tests were used
to identify differences of clinical measures between the placebo patients in each of the clusters.
In order to identify individual differences between clusters, Tukey ad hoc test was used.
All data handling and statistical analysis was performed using R software (version 3.4.1, R
Development Core Team, 2012), with use of factoextra (version 1.0.5) and pheatmap (version
Table 1. Baseline patient demographics for four cohorts used in this study, LITHE, OSKIRA, SMC1 and SMC2. All measurements were taken at the start of each of
the clinical trials prior to treatment.
LITHE OSKIRA SMC1 SMC2 p-value
Cohort characteristics
Disease Indication RA RA OA OA -
N 574 131 447 81 -
Age (± SD) 52.1 ± 12.3 � 65.7 ± 6.1 64.4 ± 6.38 < 0.001
% Female 82.8 83.2 65.4 63.5 0.26
BMI (mean ± SD) (n) 27.4 ± 6.0 (567) 27.62 ± 5.3 (131) 28.4 ± 4.9 (447) 28.5 ± 4.4 (81) 0.002
Burden of disease activity -
DAS28 6.5 ± 0.92 (563) 5.7 ± 0.81 (73) NA NA
Pain
VAS pain 54.4 ± 22.1 (568)
HAQ pain 61.3 ± 19.7 (130)
WOMAC pain 45.2 ± 19.3 (447) 50.6 ± 20.5 (81)
X-ray scores
Erosion scores 16.8 ± 16.0 (549) 21.9 ± 33.7 (131)
Kellgren Lawrence = 2 87.0% 76.5%
Kellgren Lawrence = 3 13.0% 23.5%
� Ages were reported in ranges for OSKIRA: <25 (0.7%), 25–34 (6.8%), 35–44 (13.7%), 45–54 (28.1%), 55–64 (32.8%), 65–74 (16.9%) and 75–84 (0.7%)
https://doi.org/10.1371/journal.pone.0219980.t001
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1.0.8). Permutation testing was performed using the ClusterSignificance package (version
1.4.1). Statistics were computed using the stats package (version 3.4.1).
Results
Study overview
Patients with serological markers measured at baseline (BL) were selected from study popula-
tions (N = 1233, Table 1). Patients from the OA studies (SMC01 and SMC02) were signifi-
cantly older and had significantly higher BMI than patients in the RA cohorts (LITHE and
OSKIRA) (Age, p< 0.001; BMI, p = 0.002). There was no significant difference in the percent-
age of males in the OA cohorts.
Description of clusters
Hierarchical clustering was performed based on a panel of 7 tissue specific serological bio-
markers measuring bone resorption and formation (CTX-1 and P1NP), cartilage degradation
(C2M), macrophage activity (VICM), interstitial matrix degradation (C1M and C3M), and
CRP metabolites (CRPM). This analysis revealed 5 distinct clusters from based on patient bio-
marker profiles, which can be seen in the heatmap in Fig 2. Permutation testing revealed all
clusters were statistically significantly different from each other, all with p< 0.01.
Clusters A (194 subjects) and B (256 subjects) were comprised of the majority of the RA
patients (97.9% and 98% RA patients respectively). Cluster C (188 subjects), D (363 subjects)
and E (232 subjects) contained lower percentages of RA patients (74.5%, 5.8% and 44.3%
respectively). This was reflected in the demographics and biomarker profiles of the patients. A
full description of cluster demographics and distribution can be found in Table 2.
Cluster A and B, which were predominantly RA clusters, had higher levels of C2M, CRPM,
C1M and C3M compared to clusters C, D and E. This is indicative of high levels of cartilage
turnover, CRP metabolites and interstitial matrix turnover respectively, typically observed in
RA patients[32,33]. Both bone markers (P1NP and CTX-I) were also significantly elevated in
clusters A and B in comparison to clusters C, D and E (p<0.001). Both Clusters A and B were
characterised by consistently high levels of all biomarker measures, indicating cluster A and B
appear to reflect endotypes of high disease activity. The difference between cluster A and B
was the level of VICM (macrophage activity) that was significantly lower in cluster A com-
pared to cluster B (p<0.001).
Cluster C had a mix of RA and OA patients and did not appear to have a particularly defin-
ing characteristic, all biomarker levels being close to the median. Cluster D, the largest cluster
and predominantly an OA cluster, had relatively moderate levels of tissue turnover, character-
ising patients with lower disease activity as expected of OA patients. Furthermore, cluster D
was characterised by significantly low levels of C2M, indicating lower cartilage turnover than
patients from clusters A, B and C (p< 0.01). Cluster D therefore reflects an endotype with low
bone activity, low inflammation and low cartilage activity. While cluster E, a mixed RA and
OA cluster, shared many of the characteristics of cluster D, including low levels of all inflam-
matory markers, and lower levels of cartilage turnover, a notable exception was the higher lev-
els of bone turnover biomarkers observed. Thus, cluster E appears to reflect an endotype with
high bone activity and low inflammation.
Association between clusters and RA clinical assessments in placebo patients
We looked at the RA placebo patients across the 5 clusters in order to identify differences in
clinically relevant variables (Table 3).
Serological endotyping of rheumatoid arthritis patients
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Fig 2. 1233 patients from 4 clinical trials; two rheumatoid arthritis (RA) and two osteoarthritis (OA), were clusters based on 7 tissue specific blood based
biomarkers measuring bone resorption and formation, cartilage degradation, macrophage activity, interstitial matrix degradation and CRP metabolites. 5
clusters were found with two high inflammatory RA endotypes and one low inflammatory RA endotype, and a final “mixed” endotype. OA patients were clearly
separated from RA patients as expected.
https://doi.org/10.1371/journal.pone.0219980.g002
Table 2. Descriptive statistics for each cluster identified through hierarchical clustering, with p-values calculated using ANOVA test to identify differences between
the clusters.
Clusters A B C D E p-value
N 194 256 188 363 232 -
RA/OA %
% of OA Cohort <1 9.4 9.4 65.0 24.4
% of RA Cohort 27.0 35.6 19.9 2.9 15.0
Age mean� 51.9 ± 12.7 51.4 ± 12.6 55.8 ± 11.1 64.1 ± 6.8 62.7 ± 10.1 <0.005
% Female 80.2 79.7 84.1 61.8 80.0 <0.005











% RA 97.9 98.0 74.5 5.8 44.3 -
�OSKIRA was omitted due to data being reported in ranges. P-value calculated using ANOVA or chi squared test.
https://doi.org/10.1371/journal.pone.0219980.t002
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The absolute radiographic scores (ERN, JSN and SHP) did not differ significantly at BL
between the clusters. At 52 weeks however, ΔSHP was significantly different (p = 0.03). This
was driven by ΔERN which was also significantly different between the clusters (p = 0.01),
with cluster B having the highest change in erosion (ΔERN = 1.51 ± 2.1). Tukey post-hoc anal-
ysis reveals ΔERN was significantly higher in B at 52 weeks than A (p<0.05) and C (p<0.05).
JSN did not differ between the clusters at baseline, nor ΔJSN at week 24 or week 52.
There was a significant difference in DAS28 at baseline (p<0.001) between all clusters.
Tukey post-hoc analysis shows that at baseline, DAS28 was significantly different between
cluster pairs A-E, B-C and B-E. The ΔDAS28 values at week 24 and 52 however was insignifi-
cant between the clusters (Table 3).
Age, BMI, duration of the disease, number of previous DMARDs, HAQ were statistically
insignificantly different between the RA placebo patients of all the clusters identified.
Discussion
This study was a retrospective analysis of phase III clinical studies, exploring the hypothesis
that biomarkers reflecting tissue metabolism may identify previously unrecognised RA endo-
types. We used biomarker data from two RA clinical studies, enriched with two OA studies as
a non-inflammatory arthritic population. Through clustering analysis we attempted to identify
Table 3. Mean and standard deviation of clinical variables for placebo patients in each cluster identified, where p-values have been measured using ANOVA test or
Chi squared.
Cluster A B C D E p-value
N RA 81 113 54 16 60 -
Age 51.2 ± 13.2 (58) 50.7 ± 13.3 (81) 52.9 ± 10.8 (34) 56 ± 10.3 (4) 56.9 ± 10.4 (16) 0.40
BMI 27.1 ± 4.7 (80) 28.7 ± 7.6 (113) 27.6 ± 6.5 (53) 27.8 ± 4.01 (16) 26.8 ± 5.32 (60) 0.32
Disease duration 9.8 ± 7.7 (81) 9.3 ± 8.4 (113) 9.15 ± 7.8 (54) 10.03 ± 7.91 (16) 8.8 ± 8.96 (60) 0.96
No. Prev. DMARDS 1.6 ± 1.3 (58) 1.8 ± 1.5 (81) 1.9 ± 2.1 (34) 1 ± 0.82 (4) 1.6 ± 1.8 (16) 0.83
% Previous DMARDs 63.0 (81) 61.1 (113) 61.1 (54) 43.8 (16) 45 (60) 0.139
HAQ
BL 1.5 ± 0.64 (73) 1.7 ± 0.59 (107) 1.6 ± 0.64 (53) 1.5 ± 0.61 (16) 1.6 ± 0.52 (57) 0.53
Δ24 -0.32 ± 0.61 (51) -0.43 ± 0.5 (68) -0.25 ± 0.66 (40) -0.57 ± 0.47 (15) -0.23 ± 0.4 (52) 0.08
Δ52 -0.24 ± 0.55 (25) -0.44 ± 0.64 (29) -0.62 ± 0.37 (12) 0.31 ± 0.27 (2) -0.25 ± 0.47 (6) 0.12
DAS
BL 6.3 ± 0.91 (80) 6.6 ± 0.95 (111) 6.1 ± 1.0 (53) 5.9 ± 0.93 (16) 5.7 ± 0.82 (59) <0.001
Δ24 -1.6 ± 1.1 (58) -1.4 ± 1.2 (69) -1.3 ± 1.3 (40) -1.9 ± 1.3 (15) -1.4 ± 1.2 (54) 0.46
Δ52 -2.0 ± 1.3 (28) -1.3 ± 1.5 (27) -1.7 ± 1.4 (11) -2.7 (1) -2.1 ± 1.2 (8) 0.30
JSN
BL 16.0 ± 22.0 (79) 17.8 ± 19.8 (105) 15.6 ± 24.81 (54) 13 ± 17.4 (16) 19.8 ± 34.8 (60) 0.81
Δ24 -0.01 ± 0.65 (71) 0.12 ± 0.7 (87) 0.05 ± 0.28 (45) 0.38 ± 1.5 (16) 0.15 ± 0.57 (55) 0.30
Δ52 0.32 ± 0.93 (29) 0.72 ± 1.7 (30) 0.04 ± 0.13 (14) 0 ± 0 (2) 0.18 ± 0.49 (8) 0.42
ERN
BL 18.9 ± 21.7 (79) 20.5 ± 23.3 (105) 16.6 ± 21.0 (54) 11.3 ± 15.0 (16) 20.3 ± 37.4 (60) 0.65
Δ24 0.21 ± 0.69 (71) 0.47 ± 1.2 (87) 0.18 ± 0.58 (43) 0.31 ± 1.01 (16) 0.1 ± 0.81 (54) 0.15
Δ52 0.35 ± 0.87 (29) 1.51 ± 2.1 (30) 0.15 ± 0.43 (14) 0.5 ± 0.71 (2) 0.35 ± 0.72 (8) 0.01
SHP
BL 34.9 ± 42.1 (79) 38.3 ± 41.3 (105) 32.2 ± 44.2 (54) 24.3 ± 31.5 (16) 40.1 ± 71.2 (60) 0.76
Δ24 0.2 ± 1.04 (71) 0.6 ± 1.6 (87) 0.23 ± 0.67 (43) 0.69 ± 2.5 (16) 0.28 ± 1.22 (54) 0.28
Δ52 0.68 ± 1.6 (29) 2.2 ± 3.4 (30) 0.18 ± 0.48 (14) 0.5 ± 0.71 (2) 0.52 ± 1.2 (8) 0.03
https://doi.org/10.1371/journal.pone.0219980.t003
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endotypes of RA with distinct profiles of tissue specific turnover, and identify associations
between these endotypes and indicators of clinical outcomes. The biomarkers used are mea-
sures of tissue inflammation or turnover, mainly metabolites of collagen degradation and
formation. As collagens are the main constituents of connective and calcified tissue, these bio-
markers reflect the active molecular processes in disease affected tissue[33]. Type I and type III
collagen are found in the connective tissue around the joint, as well as other affected connec-
tive tissues of the body, while type II collagen is present mainly in cartilage.
We found five distinct putative endotypes (i.e. clusters), associated with different biomarker
levels. Clusters A and B both had high levels of connective tissue and bone turnover compared
to other groups, somewhat typical of RA[7,34,35]. Conversely, clusters D and E had lower lev-
els of the connective tissue markers. Whilst this is to be expected of OA patients, RA patients
in these clusters are more unusual. These RA patients showed no significant difference in
DAS28 compared to other clusters, which could indicate a subset of RA patients that have low
connective tissue turnover in spite of high disease activity.
Both clusters A and B exhibit high levels of connective tissue markers and high rates of
bone formation and resorption, but differ in macrophage activity (VICM) and CRP metabo-
lism (CRPM). Interestingly, placebo patients in these clusters differ significantly in the rate of
radiographic progression.
Recent studies by Gu et al. showed the role macrophages play in inflammatory bone dis-
eases and the effect they have on bone formation and degradation. These studies record that
macrophage activity plays a part in bone tissue turnover[36].
Differences between diverse inflammatory and arthritic endotypes have previously been
reported by other groups[37–39]. Dennis et al. who investigated synovial biomarker traits of
certain endotypes in relation to drug response. They found four potential endotypes); i) lym-
phoid (B and plasma cell dominant), ii) a myeloid (macrophage dominant), iii) a fibroid, and
iv) a low inflammatory phenotype[37]. This may align well with the connective tissue turnover
endotypes we propose in this paper, where cluster A and B are characterised by high tissue
turnover driven by the MMP activity which are expressed by immune cells such as macro-
phages[40]. Similarly, we also found differences in the macrophage marker VICM, separating
the two high inflammatory endotypes, clusters A and B.
It is also important to note that whilst disease activity (DAS28) significantly differed across
the groups, the disease activity difference between groups A and B (inflammatory endotypes)
was insignificant, while cluster B exhibited much faster structural progression. This finding is
consistent with claims that measurement of disease activity alone it is not sufficient to identify
fast progressing RA patients who may require more a more aggressive therapeutic strategy
[41].
Presently, there are few positive examples of endotyping in the field of RA, other than sero-
positivity, and anti–cyclic citrullinated peptide, often used to classify disease. The identifica-
tion of 31 genetic risk loci in seropositive RA, including HLA–DRB1, and the group of alleles
referred to as the shared epitope, demonstrate that RA has a strong but complex genetic aetiol-
ogy. As a result, a genetic approach to the identification of biomarkers of response has been
pursued with both candidate and genome-wide level approaches[42,43]. While associations
that may ultimately lead to a greater insight into the molecular aetiology of RA have been
established, the predictive capability so far has been insufficient to have meaningful clinical
application. Indeed, Wang et al.[44] reported that each polymorphism identified in a genome-
wide association study accounted for 2% of the variance observed with a change in Disease
Activity Score in 28 joints (DAS28) response to tocilizumab, while no significant association
of polymorphisms of the target IL-6 receptor and its cognate ligand IL-6 was associated with
change in DAS28 response, following correction for multiple testing. Baseline serum or RNA
Serological endotyping of rheumatoid arthritis patients
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measurement of IL-6 or IL-6 receptor levels also provided little discrimination between
responders and non-responders, indicating that the prevalence of the target receptor or it’s
cognate ligand was not clinically deployable to identify those patients most likely to benefit
from tocilizumab[43]. There also have been attempts to utilise gene expression analysis to
identify biomarkers of biologic endotypes with superior response to treatment[45]. For exam-
ple, Kim et al. showed the importance of a differentially expressed gene, G0S2, in the response
to anti-TNF therapy, in multiple cohorts.
The findings in this study support previous proposals that RA patients have differing
underlying molecular aetiologies, and encourages further investigation into developing tools
to advance patient stratification. The prospect of identifying robust endotype profiles repre-
senting distinct disease driving pathways and networks is tantalising. Such findings have impli-
cations for the development of new precision medicines, benefiting patients, physicians and
payers[46]. If our endotypes are validated they may allow for superior treatment regime selec-
tion for the individual patients[47]; e.g. the treatment of patients with high bone remodelling,
but moderate tissue inflammation might be focused on rebalancing the bone remodelling
balance. Sivadas et al. show how whole genome sequencing has been used to identify genes
involved in drug metabolism and identification of target genes[48]. In a review by Orr et al.
they describe the advances in the use of synovial tissue for patient stratification and identifica-
tion of novel targets and biomarkers[49]. Such approached could be coupled with a serological
approach in order to improve understanding of drug metabolism and patient strata.
The strengths of this study were the large number of participants at baseline, along with
robust tissue specific markers allowing for an accurate profiling and clustering of arthritic
patients’ disease pathology. Due to the nature of clinical trials, a high placebo dropout rate
may affect the comparison of clinical endpoints. Patients enrolled in the trials had been
exposed to prior therapy including DMARDs and NSAIDs. As information regarding specific
prior treatments and ACPA positivity was not recorded or made available to us, we were
not able to correct for these possible confounders. In contrast to LITHE, which was a 52 week
placebo-controlled study, OSKIRA was a 24 week placebo-controlled study. Hence radio-
graphic endpoint for OSKIRA were only available up to 24 weeks. For this reason, in order
to reap any practical gain from this investigation, these findings must be validated in larger
cohorts with more consistent follow up measurements to show any true predictive ability of
these endotypes.
Conclusion
In conclusion this paper shows how the clustering of RA patients using tissue specific markers
allows for the identification of disease endotypes, which may have use in precision medicine
after continued research.
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